CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 15 enrolled
Drug / intervention
Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cavadevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02339974
NCT02339974Phase 3Completed
CompareCT.gov

Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation HOVER Trial

Henry Ford Health System·interventional·Posted Jan 16, 2015·Updated Jun 18, 2025

In Brief

A Phase 3 clinical trial evaluating Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava for Tricuspid Regurgitation. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The goal of this study is to determine the short term safety (\<30 days) and efficacy (6 months) of the heterotopic implantation of the Edwards-Sapien XT valve in the inferior vena cava for the treatment of severe tricuspid regurgitation in patients who are inoperable or at a very high surgical risk for tricuspid valve replacement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTricuspid Regurgitation
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 16, 2015
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2024
Study CompletionJun 1, 2025
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 11.5 years ago

Interventions

Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cavadevice